Peroxisome proliferator-activated receptor ␥ (PPAR␥) is a member of the nuclear receptor superfamily of ligand-activated transcription factors and is expressed in several types of tissue. Although PPAR␥ reportedly is expressed in normal urothelium, its function is unknown. We examined the expression of PPAR␥ in normal urothelium and bladder cancer in an attempt to assess its functional role. Immunohistochemical staining revealed normal urothelium to express PPAR␥ uniformly. All low-grade carcinomas were positive either diffusely or focally, whereas staining was primarily focal or absent in high- The peroxisome proliferator-activated receptor ␥ (PPAR␥) is a member of the nuclear receptor superfamily of ligand-activated transcription factors and functions as a regulator of adipocyte differentiation and lipid metabolism.
The peroxisome proliferator-activated receptor ␥ (PPAR␥) is a member of the nuclear receptor superfamily of ligand-activated transcription factors and functions as a regulator of adipocyte differentiation and lipid metabolism. 1, 2 PPAR␥ is expressed in several types of tissue including the kidney, spleen, colon, breast, and urinary tract as well as adipose tissue. [3] [4] [5] [6] Recent studies indicate that this receptor can induce differentiation in liposarcoma cells, 7 monocytes/macrophages, 8 and breast cancer cells in vitro. 9 Furthermore, it has been shown that the growth of colon cancer cells and androgen-independent prostate cancer cells is inhibited by treatment with PPAR␥ agonists in vitro and in vivo. 10, 11 Although these studies suggest that PPAR␥ may be a potential target for cancer treatment, Lefebvre and colleagues 12 and Saez and colleagues 13 demonstrated that PPAR␥ agonists promoted the development of colorectal tumors in mice.
We are interested in elucidating the role of PPAR␥ and its ligands in bladder cancer. Despite its rich expression in normal urothelium, the role of PPAR␥ in the urothelium is unknown. 5, 6 One of the natural ligands for PPAR␥, prostaglandin D metabolite 15-deoxy-⌬ 12,14 -prostaglandin J 2 (15d-PGJ 2 ), 14, 15 is present in urine abundantly. 16 In this study, we examined the expression of PPAR␥ protein in normal human urothelium and bladder carcinoma tissue by immunohistochemistry, and tested the effect of two classes of ligands for PPAR␥, 15d-PGJ 2 , and troglitazone (TRO) and pioglitazone (PIO) (thiazolidinedione derivatives) 10 on the growth of nonneoplastic and neoplastic human urothelial cells in vitro.
Materials and Methods

Immunohistochemistry
Portions of normal ureter derived from 3 nephrectomy specimens removed for renal cell carcinoma, 2 normal bladder mucosal biopsies, and 48 bladder carcinoma specimens removed transurethrally were used. Excised specimens were fixed immediately in cold 4% paraformaldehyde (EM Science, Gibbstown, NJ) solution. After overnight fixation in the refrigerator, they were processed by the routine procedure and embedded in paraffin. Before staining, sections mounted on poly-L-lysine-coated slides were deparaffinized with xylene, and rehydrated in graded ethanol. For the purpose of antigen retrieval, sections were incubated in Target retrieval solution (DAKO, Carpinteria, CA) at 95°C for 20 minutes and cooled at room temperature for 20 minutes. After blocking with 3% horse serum in phosphate-buffered saline, samples were incubated at room temperature for 3 hours with the monoclonal mouse anti-PPAR␥ antibody (E-8, lot no.H218; Santa Cruz Biotechnology, Santa Cruz, CA) or the polyclonal rabbit anti-PPAR␥1, 2 antibody (Calbiochem, San Diego, CA) diluted to 1:50 or 1:2000 with the blocking solution, and for the subsequent steps the avidin-biotin-peroxidase complex method with a Vectastain ABC kit (Vector, Burlingame, CA) was used. Carcinomas were graded according to the World Health Organization classification. 17 
Cells and Cell Culture
The three human bladder carcinoma cell lines used were RT4, T24, and 253J. 18 The cells were grown in Ham's F12 (RT4 and T24) or RPMI 1640 (253J) medium supplemented with 5% fetal bovine serum, 100 U/ml penicillin, and 100 g/ml streptomycin (Life Technologies, Gaithersburg, MD) in a humidified atmosphere of 95% air and 5% CO 2 at 37°C.
An immortalized nonneoplastic human urothelial cell line (1T-1) was established in our laboratory. 19 It originated from Hu1 cells 20 that were derived from the ureter of a 71-year-old male undergoing nephrectomy for renal cell carcinoma. The benign nature of the starting material was confirmed by histological examination of the remaining portion of the ureter. Seven days after plating when epithelial outgrowth from explants reached ϳ2 cm in diameter, infection with an amphotrophic retrovirus vector LXSN16E6E7, containing E6 and E7 genes of human papilloma virus type 16 (kindly provided by Dr. D. Galloway, Fred Hutchinson Cancer Center, Seattle, WA) was performed overnight in 4 ml of keratinocyte serum-free medium (K-SFM; Life Technologies) in the presence of 4 g/ml of polybrene (Sigma, St. Louis, MO). G418 (Life Technologies) at 200 g/ml was added at 48 hours for selection of immortalized cells. Cells at passage 16 were subjected to soft agar assay 19 and several colonies were picked up, expanded, and designated as 1T-1, 1T-2, and 1T-3. One of the clones (1T-1) was used. 1T-1 cells were maintained in K-SFM supplemented with 50 g/ml bovine pituitary extract, 5 ng/ml epidermal growth factor, 100 U/ml penicillin, and 100 g/ml streptomycin (Life Technologies) in a humidified atmosphere of 95% air and 5% CO 2 at 37°C.
Isolation of RNA for Reverse TranscriptasePolymerase Chain Reaction (RT-PCR)
Cytoplasmic RNA from cultured cells was extracted as follows. Cells grown in monolayers were harvested at an early confluency. RNA was prepared by lysing cells in hypotonic buffer containing Nonidet P-40 (Sigma), followed by removal of nuclei. Cytoplasmic RNA was reverse-transcribed by Moloney murine leukemia virus reverse transcriptase (Life Technologies) at 42°C for 60 minutes with the use of random primers (5 mol/L; Life Technologies). Subsequently, 1 l of the product was subjected to PCR amplification. PCR was performed as follows. The final concentration of deoxynucleotide triphosphates and primers in the reaction mixture was 200 mol/L and 1 mol/L, respectively. Taq DNA polymerase (Cetus Perkin-Elmer, Norwalk, CT) was added to the mixture at a final concentration of 0.05 U/ml, and the reaction was performed in a DNA thermal cycler (Cetus Perkin-Elmer). To amplify PPAR␥1 (790 bp) and PPAR␥2 (877 bp), the nucleotide bases used were 5Ј-CCG CTC GAG CGG GCC GCC GTG GCC GCA GAA-3Ј as an upstream primer for human PPAR␥1, 5Ј-CCG CTC GAG CGG AAA CCC CTA TTC CAT GC-3Ј as an upstream primer for human PPAR␥2, and 5Ј-AGG AAT TCA TGT CAT AGA TAA CG-3Ј as a downstream primer for both PPAR␥1 and 2 and 5Ј-GAA ATC CCA TCA CCA TCT TCC AGG-3Ј as an upstream primer and 5Ј-CAT GTG GGC CAT GAG GTC CAC CAC-3Ј as a downstream primer for glyceraldehyde-3-phosphate dehydrogenase. 21 
Western Blotting
Cells grown in monolayers were harvested at subconfluency and lysed with a lysing buffer [62.5 mmol/L Tris (pH 6.8), 2% sodium dodecyl sulfate, 10% glycerol, 5% ␤-mercaptoethanol, and 7 mol/L urea] (Sigma). The sample was boiled for 10 minutes and was then forcefully passaged five times through a 25-gauge needle. The samples were centrifuged at 12,000 ϫ g for 10 minutes and the precipitates were discarded. Fifty-g protein samples of the supernatant were electrophoresed on 10% sodium dodecyl sulfate-polyacrylamide gel. Protein was transferred to polyvinylidene difluoride membrane (Bio-Rad, Hercules, CA), and the membrane was incubated with an anti-PPAR␥ antibody (E-8; Santa Cruz Biotechnology or Calbiochem), anti-PPAR binding protein (PBP) antibody, 22 or anti-retinoid X receptor ␣ (RXR␣) antibody (D-20; Santa Cruz Biotechnology) and treated with an enhanced chemiluminescence kit (Amersham, Arlington Heights, IL). Densitometric analysis was done with an NIH Image 1.59.
Cell Growth Assay
Cells were seeded on a flat-bottom 96-well plate (Falcon, Becton Dickinson, Franklin Lakes, NJ) at the density of 2 ϫ 10 3 (1T-1, T24, and 253J) or 5 ϫ 10 3 (RT4) cells per well in the respective appropriate growth medium. Twenty-four hours later, cells were grown in the same medium containing 15d-PGJ 2 (0 to 10 mol/L; Cayman Chemical, Ann Arbor, MI), TRO (0 to 50 mol/L; a gift from ParkeDavis, Ann Arbor, MI), or PIO (0 to 50 mol/L; a gift from Takeda Chemical Industries, Ltd., Tokyo, Japan). After 24 hours of incubation, cell proliferation was assessed by Cell proliferation enzyme-linked immunosorbent assay, BrdU (Roche Molecular Biochemicals, Mannheim, Germany). We also assessed cell number by manual counting; cells were seeded on a flat-bottom 6-well plate (Falcon, Becton Dickinson) at the density of 5 ϫ 10 4 cells per well. Twenty-four hours later, cells were treated with above PPAR␥ ligands. After 3 days, cells were recovered by treatment with 0.05% trypsin-0.53 mmol/L ethylenediaminetetraacetic acid (Life Technologies) and counted with a hemocytometer.
Transfections and Luciferase Assay
Cells were seeded on a flat-bottom 6-well plate (Falcon, Becton Dickinson) at the density of 3 ϫ 10 5 cells per well in the respective appropriate growth medium. Twentyfour hours later, transfection was done by using the Effectene transfection reagent (Qiagen, Valencia, CA) mix with a reporter plasmid PPRE (PPAR response elements)-TK-LUC produced in our laboratory. 23 The PPRE-TK-LUC was constructed by inserting three copies of PPRE (AG-GACAAAGGTCA) into HindIII/SalI site of TK-LUC. The transfection mix was replaced with the complete medium with or without PPAR␥ ligands (15d-PGJ 2 and TRO) and was further incubated for 24 hours. The cells were lysed with cell culture lysis reagent (Promega, Madison, WI). Luciferase activity was measured with the use of a luciferase assay reagent (Promega) in a scintillation counter (Aloka, Tokyo, Japan).
Results
Immunohistochemical Demonstration of PPAR␥ Protein in Normal Urothelium and Bladder Cancer Tissue
PPAR␥ protein was uniformly expressed in the urothelium of three normal ureters and two normal bladder mucosal biopsies and was localized to nuclei ( Figure 1A ). The staining reaction was more intense in the superficial and intermediate cells than in the basal cells. Localization and staining intensity were similar when the results with the two antibodies were compared. Expression of PPAR␥ protein in bladder carcinoma cells is summarized in Table 1. All cases of transitional cell carcinomas of low grades (grade 1 and 2) demonstrated an intense nuclear staining either in all cells or focally up to 90% of tumor cells ( Figure 1B) . In contrast, staining was focal to absent in high-grade carcinomas (Figure 1, C and D) . Statistically significant loss of PPAR␥ expression was evident in grade 3 carcinomas as compared to the expression in 
Expression in Vitro of PPAR␥ in Nonneoplastic and Neoplastic Urothelial Cells
First, we examined the expression of PPAR␥ mRNA in immortalized nonneoplastic and neoplastic urothelial cells. PPAR␥1 mRNA was detected by RT-PCR in all cell types whereas PPAR␥2 mRNA was expressed only in RT4 cells (Figure 2A) . By Western blotting, PPAR␥ (ϳ58 kd) was detected at varying levels in all cell types ( Figure  2B ). Expression of PPAR␥ protein was reduced by 49, 63, and 68%, respectively, in RT4, T24, and 253J cells as compared to the expression in 1T-1 cells. By immunocytochemical staining, the protein was uniformly localized to nuclei in all cells in all cell lines (data not shown).
Effect of 15d-PGJ 2 , TRO, and PIO on Growth in Vitro of Nonneoplastic and Neoplastic Urothelial Cells
We next tested the effect of PPAR␥ ligands on the growth of immortalized nonneoplastic and neoplastic cells. Treatment with PPAR␥ ligands suppressed the growth of all tested cells in a dose-dependent manner (Figure 3) . Low-dose 15d-PGJ 2 (0.5 mol/L) almost completely inhibited the growth of 1T-1 cells. In contrast, all carcinoma cell lines were resistant to its suppressive effect at concentrations up to 1 to 5 mol/L ( Figure 3A) . The response to TRO was similar to that to 15d-PGJ 2 ; low-dose TRO (2 to 8 mol/L) strikingly suppressed the growth of 1T-1 cells. Cancer cells were more resistant; complete suppression required TRO at a much higher concentration (20 mol/L for RT4 and 50 mol/L for T24). 253J cells were more resistant and 50% of cells survived at 50 mol/L ( Figure 3B ). Treatment with another synthetic PPAR␥ ligand, PIO, also showed the similar inhibitory effect on nonneoplastic and neoplastic human urothelial cell lines except 253J cells ( Figure 3C ).
Ligand-Induced Transcriptional Activity of PPAR␥
We examined the transcriptional activity of PPAR␥ using a luciferase reporter plasmid containing a PPAR␥ response element. TRO ranging from 0.1 mol/L to 50 mol/L and 15d-PGJ 2 
Expression of PBP and RXR␣ Protein in Nonneoplastic and Neoplastic Urothelial Cells
We examined the expression of PBP, a PPAR␥ co-activator, and RXR␣, a PPAR␥ heterodimeric partner, by Western blotting. PBP protein (ϳ165 kd) was detected only in RT4 cells ( Figure 5 ). RXR␣ protein (ϳ55 kd) was expressed in all cell lines. 1T-1 and RT4 cells expressed RXR␣ protein at a much higher level than did T24 and 253J cells ( Figure 5 ).
Then we tested synergistic effect of a RXR␣ ligand, 9-cis-retinoic acid (9-cis-RA) on a PPAR␥ ligand. In RT4, T24, and 253J cells, 9-cis-RA (5 mol/L) enhanced the inhibitory effect of TRO by 1.1-fold, 1.5-fold, and twofold, respectively. The growth of 1T-1 cells was inhibited completely by treatment with 9-cis-RA (5 mol/L) alone whereas it had no effect on the growth of all carcinoma cell lines (data not shown).
Discussion
Previous studies have reported that PPAR␥ ligands mostly inhibit the growth of breast, 9 prostate, 10 and colon cancer 11 cells in vitro and in vivo. We demonstrated here that PPAR␥ was expressed in nonneoplastic and neoplastic urothelial cell lines at both mRNA and protein levels. However, the sensitivity to the inhibitory effects by RT-PCR for expression of PPAR␥1 and -2 mRNA. All samples demonstrate PPAR␥1 message whereas PPAR␥2 was expressed only in RT4 cells. Primers specific for PPAR␥1 and -2 and glyceraldehyde-3-phosphate dehydrogenase cDNAs generated fragments of 790 bp, 877 bp, and 782 bp, respectively. B: Western blot analysis for PPAR␥ protein. Cell lysates were isolated and electrophoresed on 10% sodium dodecyl sulfatepolyacrylamide gel (50 g of protein/lane). Proteins from gels were transferred to polyvinylidene difluoride membrane, and PPAR␥ was detected with mouse monoclonal anti-PPAR␥ antibody and an enhanced chemiluminescence kit. All samples demonstrate PPAR␥ protein (ϳ58 kd).
PPAR␥ ligands (15d-PGJ 2 , TRO, and PIO) was variable. Nonneoplastic urothelial cell line 1T-1 was sensitive to the inhibitory effects of PPAR␥ ligands. In contrast, carcinoma cell lines were resistant.
Studies by others using various carcinoma cell lines all indicate that PPAR␥ ligands reduce growth rate. 10, 11, 24, 25 Thus PPAR␥ ligands have been suggested to be a useful therapeutic agent for breast, prostate, or colon carcinomas. 9 -11 The rationale behind this approach is that whereas normal cells either do not express PPAR␥ or, if they express, only at a very low level, whereas carcinoma cells express the receptor abundantly. 10 This allows selective action of PPAR␥ ligands on neoplastic cells and induces cell death or differentiation. However, there have been recent reports indicating that treatment with a PPAR␥ ligand promotes the development of colon tumor in Minϩ/Ϫ mice that lack one functional copy of the APC tumor suppresser gene. 12, 13 Normal human ureter reportedly expressed PPAR␥ protein. 5 In the present study, we confirmed this observation. However, in bladder carcinoma tissues as well as in carcinoma cell lines, its expression seemed affected by the degree of malignancy: in low-grade (grades 1 and 2) carcinomas, PPAR␥ protein was uniformly or diffusely demonstrated by immunohistochemistry, whereas in high-grade (grade 3) carcinomas the expression of PPAR␥ protein was mostly heterogeneous or absent. , and PIO (C) on growth of nonneoplastic and neoplastic urothelial cells. Cells were seeded on a 96-well or 6-well plate in the medium with 5% fetal bovine serum appropriate for each cell type. Twenty-four hours later, medium was changed to the same medium containing 15d-PGJ 2 (0 to 10 mol/L), TRO (0 to 50 mol/L), or PIO (0 to 50 mol/L). After incubation for 24 hours, cell proliferation was assessed by cell proliferation enzyme-linked immunosorbent assay, BrdU kit. After 3 days, the number of cells was counted with a hemocytometer after cells were recovered by trypsinization. Results are expressed as ratio to the respective control culture. Bars denote SD of triplicate samples. The ligand concentrations in the abscissa are on an arbitrary scale. *, P Ͻ 0.0001 compared with the respective control culture.
In the in vitro study we demonstrated that high-grade carcinoma cell lines T24 and 253J expressed RXR␣ at a lower level than did the nonneoplastic cell line 1T-1 and a low-grade carcinoma cell line RT4. Expression of cofactor PBP was almost exclusive to RT4 cells. The luciferase reporter assay indicates that ligand-induced transcriptional activity of PPAR␥ is most active in 1T-1 in which a fivefold to sixfold increase was observed at the TRO concentration as low as 0.1 mol/L. On the other hand, transcriptional activity of carcinoma cells was low (up to twofold) requiring ligand concentrations as high as 10 to 20 mol/L. Treatment with 15d-PGJ 2 did not induce transcriptional activity. It is possible that mutations in PPAR␥ gene may affect ligand-dependent transcriptional activity. 26, 27 In human colon cancer, 26 two missense mutations were detected in the ligand-binding domain and impaired the function of the protein. One of mutations showed a normal response to synthetic ligands but decreased transcription when exposed to natural ligands. Though 15d-PGJ 2 significantly inhibited the growth of neoplastic urothelial cells, it induced no PPRE luciferase activity. The result suggests that the growth-inhibitory action of 15d-PGJ 2 may depend on some other mechanisms. For example, according to a recent report, 28 15d-PGJ 2 is a direct inhibitor of IkB kinase (IKK␤) and prevents nuclear factor-kB activation.
Based on these observations we suggest several mechanisms to account for the differential response of urothelial cells to PPAR␥ ligands: nonneoplastic cells are highly sensitive to their cytocidal effects because of their efficient transcriptional activity whereas carcinoma cells are resistant because of low transcriptional activity or because of their failure to express PPAR␥. Our data suggest that intravesical administration of PPAR␥ ligand in an attempt to treat bladder cancer may result in severe cytotoxic effects on normal urothelial cells before therapeutic effects on cancer cells can be demonstrated. Furthermore some cancer may be totally refractory because of their mutations or failure to express PPAR␥. Additional studies are needed before therapy with PPAR␥ ligands is attempted. were seeded on a 6-well plate in the medium appropriate for each cell type. Twenty-four hours later, transient transfection was done by using Effectene transfection reagent with PPRE-TK-LUC. The transfection mix was replaced by complete medium with or without TRO (0.1, 10, or 20 mol/L) and incubated for an additional 24 hours. The cells were lysed with cell culture lysis reagent. Luciferase activity was measured by using luciferase assay reagent in a scintillation counter. Results are expressed as ratio to the respective control culture. Bars denote SD of triplicate samples. *, P Ͻ 0.0001 compared with the respective control culture. Proteins from gels were transferred to polyvinylidene difluoride membrane, and PBP and RXR␣ were detected with rabbit anti-PBP and -RXR␣ antibody and an enhanced chemiluminescence kit. Only RT4 cells demonstrate PBP protein. RXR␣ expression is at much higher levels in 1T-1 and low-grade carcinoma cell line RT4 than in high-grade carcinoma cell lines T24 and 253J.
